Table 14.
Antimicrobial resistance in Salmonella Kentucky from humans per country in 2016
| Country | Gentamicin | Chloramphenicol | Ampicillin | Cefotaxime | Ceftazidime | Meropenem | Tigecycline | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Austria | 10 | 30.0 | 10 | 40.0 | 10 | 80.0 | 10 | 0 | 10 | 0 | 10 | 0 | 10 | 0 |
| Belgium | 28 | 46.4 | 28 | 10.7 | 28 | 64.3 | 28 | 3.6 | 28 | 3.6 | 28 | 0 | – | – |
| Cyprus | 1 | NA | – | – | 1 | NA | – | – | 1 | NA | 1 | NA | – | – |
| Denmark | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA |
| Finland | 1 | NA | 1 | NA | 1 | NA | 1 | NA | – | – | 1 | NA | – | – |
| France | 10 | 50.0 | 10 | 0 | 10 | 60.0 | 10 | 10.0 | 10 | 0 | 10 | 0 | 10 | 0 |
| Germanya | 37 | 54.1 | 38 | 5.3 | 38 | 71.1 | 38 | 7.9 | 38 | 7.9 | 38 | 0 | – | – |
| Greece | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | – | – |
| Ireland | 4 | NA | 4 | NA | 4 | NA | 4 | NA | 4 | NA | 4 | NA | 4 | NA |
| Luxembourg | 3 | NA | 3 | NA | 3 | NA | 3 | NA | 3 | NA | 3 | NA | – | – |
| Maltaa | – | – | – | – | 20 | 95.0 | 20 | 65.0 | 20 | 65.0 | 20 | 0 | – | – |
| Netherlands | 26 | 53.8 | 26 | 0 | 26 | 65.4 | 26 | 30.8 | 26 | 30.8 | 26 | 0 | 26 | 3.8 |
| Slovenia | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | – | – |
| Spain | 9 | NA | 9 | NA | 9 | NA | 9 | NA | 9 | NA | 9 | NA | – | – |
| United Kingdoma | – | – | 22 | 0.0 | 33 | 72.7 | 16 | 0 | 6 | NA | 8 | NA | – | – |
| Total (MSs 16) | 132 | 44.7 | 154 | 6.5 | 186 | 71.0 | 168 | 15.5 | 158 | 17.1 | 161 | 0 | 51 | 2.0 |
| Icelanda | – | – | 1 | NA | 1 | NA | – | – | – | – | – | – | – | – |
| Norway | 3 | NA | 1 | NA | 3 | NA | 3 | NA | 3 | NA | 3 | NA | – | – |
| Country | Nalidixic acid | Ciprofloxacinb | Azithromycin | Colistin | Sulfamethoxazolec | Trimethoprim | Co‐trimoxazole | Tetracycline | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
| Austria | 10 | 90.0 | 7 | NA | – | – | – | – | 10 | 70.0 | 10 | 20.0 | – | – | 10 | 70.0 |
| Belgium | 28 | 89.3 | 28 | 89.3 | 28 | 0 | – | – | 28 | 60.7 | 13 | 7.7 | – | – | 28 | 75.0 |
| Cyprus | – | – | – | – | – | – | 1 | NA | – | – | – | – | – | – | – | – |
| Denmark | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | – | – | 1 | NA |
| Finland | 1 | NA | 1 | NA | – | – | – | – | – | – | 1 | NA | – | – | 1 | NA |
| France | 10 | 90.0 | 10 | 90.0 | 10 | 0 | 10 | 0 | 10 | 90.0 | 10 | 10.0 | – | – | 10 | 80.0 |
| Germanya | 38 | 86.8 | 38 | 78.9 | – | – | – | – | – | – | – | – | 38 | 5.3 | 38 | 68.4 |
| Greece | 1 | NA | 1 | NA | – | – | – | – | 1 | NA | 1 | NA | – | – | 1 | NA |
| Ireland | 4 | NA | 4 | NA | 4 | NA | 1 | NA | 4 | NA | 4 | NA | – | – | 4 | NA |
| Luxembourg | – | – | 3 | NA | – | – | – | – | 3 | NA | 3 | NA | 3 | NA | 3 | NA |
| Maltaa | – | – | 20 | 95.0 | – | – | – | – | – | – | – | – | – | – | – | – |
| Netherlands | 26 | 92.3 | 26 | 92.3 | 26 | 3.8 | 26 | 0 | 26 | 73.1 | 26 | 11.5 | – | – | 26 | 69.2 |
| Slovenia | – | – | 1 | NA | – | – | – | – | 1 | NA | 1 | NA | 1 | NA | 1 | NA |
| Spain | 9 | NA | 9 | NA | – | – | – | – | 9 | NA | 9 | NA | – | – | 9 | NA |
| United Kingdoma | 14 | 85.7 | 34 | 79.4 | – | – | – | – | 6 | NA | 17 | 5.9 | 8 | NA | 9 | NA |
| Total (MSs 16) | 142 | 87.3 | 183 | 85.8 | 69 | 1.4 | 39 | 0 | 99 | 68.7 | 96 | 8.3 | 50 | 6.0 | 141 | 71.6 |
| Icelanda | – | – | 1 | NA | – | – | – | – | – | – | – | – | 1 | NA | – | – |
| Norway | – | – | 3 | NA | 1 | NA | – | – | – | – | – | – | 3 | NA | 1 | NA |
N: number of isolates tested; % Res: percentage of microbiologically resistant isolates [either interpreted as non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories]; –: no data reported; NA: not applicable – if fewer than 10 isolates were tested, the percentage of resistance was not calculated; MS: Member State.
a
Provided measured values. Data interpreted by ECDC.
b
Ciprofloxacin has in several countries been replaced by pefloxacin for screening of fluoroquinolone resistance with disc diffusion, as recommended by EUCAST.
c
Combined data on the class of sulfonamides and the substance sulfamethoxazole within this group.